FindTrial
Sign In

NUDT15 genetic variations and 6-mercaptopurine tolerance in Chinese children with acute lymphoblastic leukemia

NUDT15 genetic variations and 6-mercaptopurine tolerance in Chinese children with acute lymphoblastic leukemia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800019786
Enrollment
Unknown
Registered
2018-11-28
Start date
2019-01-01
Completion date
Unknown
Last updated
2018-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute lymphoblastic leukemia

Interventions

Case series:Nil

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Diagnosed acute lymphoblastic leukemia; (2) Aged one month to 18 years old; (3) Patients receive chemotherapy with CCLG-ALL2008 or CCCG-ALL-2015 regimen; (4) Patients with complete blood and liver and kidney function test results before and after taking 6-MP; (5) Patients have completed 6 cycles of maintenance treatment; (6) Patients with complete information related to this research.

Exclusion criteria

Exclusion criteria: (1) Patients with incomplete clinical and pathological data that cannot be statistically analyzed; (2) Patients without access to blood samples for genetic analysis; (3) Any condition that the investigator considers unsuitable for participation in the clinical study.

Design outcomes

Primary

MeasureTime frame
NUDT15;—

Countries

China

Contacts

Public ContactYong Han

Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

whxhhanyong@163.com+86 15337295176

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026